Spotlight
Clinical
Events
CME
Partners
Subscribe
- COVID-19
- Biosimilars
- Cataract Therapeutics
- DME
- Gene Therapy
- Workplace
- Ptosis
- Optic Relief
- Imaging
- Geographic Atrophy
- AMD
- Presbyopia
- Ocular Surface Disease
- Practice Management
- Pediatrics
- Surgery
- Therapeutics
- Optometry
- Retina
- Cataract
- Pharmacy
- IOL
- Dry Eye
- Understanding Antibiotic Resistance
- Refractive
- Cornea
- Glaucoma
- OCT
- Ocular Allergy
- Clinical Diagnosis
- Technology
Glaucoma 360 panelist shares industry update on new drugs, drops
Ellie Chabi, MD, Therapeutic Area Head for Glaucoma & Neuroprotection and Lead for Artificial Intelligence Programs within Global Biomedical Science for Santen, provides an update on its glaucoma pipeline.
Ellie Chabi, MD, is Therapeutic Area Head for Glaucoma & Neuroprotection, Lead for Artificial Intelligence Programs within Global Biomedical Science for Santen, shares insights from the industry panel discussion, "Drugs and Drops" at the 23rd annual Glaucoma 360 meeting at the Palace Hotel in San Francisco on Feb. 2, 2019.
Related Videos
Related Content
